Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Rating of “Hold” from Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been given an average rating of “Hold” by the twenty-two analysts that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $107.3333.

Several equities analysts have commented on the stock. The Goldman Sachs Group lowered shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective for the company. in a research report on Friday, January 9th. Robert W. Baird reiterated a “neutral” rating and issued a $100.00 price target (down previously from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th. Canaccord Genuity Group decreased their price objective on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating on the stock in a research report on Monday, November 10th. Evercore ISI upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their target price for the stock from $94.00 to $120.00 in a report on Monday, January 5th. Finally, Citigroup lowered their price target on Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating for the company in a research report on Thursday, December 11th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ZBH. Brighton Jones LLC purchased a new position in Zimmer Biomet during the 4th quarter valued at $204,000. Focus Partners Wealth boosted its stake in shares of Zimmer Biomet by 2.6% during the first quarter. Focus Partners Wealth now owns 16,955 shares of the medical equipment provider’s stock valued at $1,919,000 after purchasing an additional 427 shares during the period. Czech National Bank increased its stake in Zimmer Biomet by 5.8% in the 2nd quarter. Czech National Bank now owns 48,361 shares of the medical equipment provider’s stock worth $4,411,000 after buying an additional 2,637 shares during the period. Pallas Capital Advisors LLC bought a new stake in Zimmer Biomet during the 2nd quarter valued at about $307,000. Finally, Bruce G. Allen Investments LLC boosted its position in Zimmer Biomet by 30.1% in the 2nd quarter. Bruce G. Allen Investments LLC now owns 1,098 shares of the medical equipment provider’s stock valued at $100,000 after buying an additional 254 shares during the period. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $86.65 on Thursday. The business’s 50-day moving average is $91.47 and its 200 day moving average is $96.34. Zimmer Biomet has a 12 month low of $85.33 and a 12 month high of $114.44. The company has a market capitalization of $17.17 billion, a P/E ratio of 21.45, a P/E/G ratio of 2.21 and a beta of 0.62. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The company’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts forecast that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Tuesday, December 30th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio is presently 23.76%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.